Ad
Monday, 26 March 2018
Roche's Tecentriq cocktail notches another lung cancer success
ZURICH (Reuters) - Roche's immunotherapy Tecentriq combined with other drugs boosted lung cancer patients' survival versus an older cocktail, the Swiss company's latest trial success as it seeks an edge on Merck and Bristol-Myers Squibb.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment